Spectral Medical Inc. announced the onboarding of the Mayo Clinic in Rochester, Minnesota, as its 19th clinical site for the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion ("PMX") in a randomized controlled trial of adults being treated for endotoxemia and septic shock. The Mayo Clinic is a premier medical center in the U.S. and is top ranked in more specialties than any other hospital in the nation, according to U.S. News & World Report.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.49 CAD | -3.92% |
|
-3.92% | +15.29% |
07/06 | Transcript : Spectral Medical Inc. - Shareholder/Analyst Call | |
30/05 | Spectral Medical Closes C$8.5 Million Convertible Notes Financing | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.29% | 99.94M | |
+42.47% | 630B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 298B | |
+17.96% | 246B | |
+0.74% | 225B | |
+10.95% | 218B | |
+3.68% | 160B | |
-4.38% | 156B |
- Stock Market
- Equities
- EDT Stock
- News Spectral Medical Inc.
- Spectral Medical Inc. Announces Opening of Tigris Clinical Trial Site At the Mayo Clinic